Dr. Stacey M. Stein, MD

Dr. Stein practices at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health.

Dr. Stein's NPI, 1285824706, was assigned on July 31, 2007. Dr. Stein holds New Jersey license 25MA12494500.

Dr. Stein's primary practice is Robert Wood Johnson University Hospital, at One Robert Wood Johnson Place, New Brunswick, NJ 08901 in Middlesex County. The practice phone is (732) 828-3000. Dr. Stein also practices at Robert Wood Johnson University Hospital - New Brunswick, 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901.

Dr. Stein's primary practice is Robert Wood Johnson University Hospital in New Brunswick, New Jersey, part of RWJBarnabas Health. Dr. Stein is also affiliated with Yale New Haven Hospital. The medical group on file is Rutgers-RWJ Scleroderma Program.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Stein practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Stein's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Stein's licenses on file in 2 states: New Jersey and Connecticut.

CMS data shows 306 Medicare services from Dr. Stein across 4 procedure codes in 2024, for 107 Medicare patients. Medicare paid $24,693 for them.

CMS counts 107 Medicare patients who saw Dr. Stein in 2024. The largest group is 65 to 74, with 47 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Stein's median patient age at 70, with 42% women.

In 2024, Dr. Stein wrote 291 Medicare Part D claims for 53 patients. 51% of them were for generic drugs. CMS names the drug for 162 of them, across 5 drugs with 11 or more claims each, at $925,575 in total drug cost. In 2023, CMS named 54 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Stein for performance year 2024, reported as part of a group. Dr. Stein accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Stein as offering telehealth.

Dmand AI links 53 papers to Dr. Stein, published from 2012 to 2025. 2021 was the busiest year, with 8. The most frequent topics are Liver Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Carcinoma, Hepatocellular. Dr. Stein has published most often in J Gastrointest Oncol. Dr. Stein's most frequent co-authors are Jill Lacy, MD, Michael Cecchini, MD and Kimberly Lauren Johung, MD, PhD.

Dmand AI links Dr. Stein to 10 clinical trials, 5 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Rectal Diseases, Bile Duct Neoplasms and Camurati-Engelmann Syndrome. Leap Therapeutics, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Stein that name 1 trial.

CMS Open Payments shows 164 general payments to Dr. Stein from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. Genentech, Inc. paid the most, $30,417. It also lists 5 research payments totaling $11,599 from 2020 to 2023, naming 1 clinical trial.